Key facts
- Medrhythms’s last known valuation is $85.0M (Jan 2024).
- It has raised $61.8M across 7 recorded rounds; the latest was Seed Round ($3.3M) in Feb 2026.
- Notable investors include Global Brain, Harvard Innovation Launch Lab, Morningside Group, Peterson Partners, Maine Venture Fund — 14 tracked in total.
- Medrhythms has filed 7 Form Ds with the SEC since 2018, most recently Apr 2025 ($2.9M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Medrhythms
Funding rounds
7 roundsAbout Medrhythms
Provider of neurologic music therapy intended to offer evidence-based neurologic interventions to measure and improve walking. The company's clinical programs use sensors, artificial intelligence, and music to develop neurologic interventions and also provide direct stimulation to help in the mechanism of action in each relevant population, enabling patients to use music to directly stimulate the brain and improve functional outcomes.
- Sector
- Healthcare
- HQ
- Portland, ME, United States
- Founded
- 2013
- Employees
- 46
- Website
- medrhythms.com/
- Ownership
- Privately Held (backing)
Medrhythms doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medrhythms shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medrhythms in its N-PORT filings yet. We sweep new filings monthly.